378 related articles for article (PubMed ID: 19436665)
1. Redefining the role of thiazolidinediones in the management of type 2 diabetes.
Barnett AH
Vasc Health Risk Manag; 2009; 5(1):141-51. PubMed ID: 19436665
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone is a valid alternative to rosiglitazone.
Derosa G
Am J Cardiovasc Drugs; 2011 Dec; 11(6):357-62. PubMed ID: 21950735
[TBL] [Abstract][Full Text] [Related]
3. Thiazolidinediones in type 2 diabetes mellitus: current clinical evidence.
Diamant M; Heine RJ
Drugs; 2003; 63(13):1373-405. PubMed ID: 12825962
[TBL] [Abstract][Full Text] [Related]
4. Thiazolidinediones: effects on the development and progression of type 2 diabetes and associated vascular complications.
Krentz A
Diabetes Metab Res Rev; 2009 Feb; 25(2):112-26. PubMed ID: 19219860
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
Defronzo RA; Mehta RJ; Schnure JJ
Hosp Pract (1995); 2013 Apr; 41(2):132-47. PubMed ID: 23680744
[TBL] [Abstract][Full Text] [Related]
6. A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors.
Chiquette E; Ramirez G; Defronzo R
Arch Intern Med; 2004 Oct; 164(19):2097-104. PubMed ID: 15505122
[TBL] [Abstract][Full Text] [Related]
7. The "glitazones": rosiglitazone and pioglitazone.
Papoushek C
J Obstet Gynaecol Can; 2003 Oct; 25(10):853-7. PubMed ID: 14532954
[TBL] [Abstract][Full Text] [Related]
8. Pioglitazone: a review of its use in type 2 diabetes mellitus.
Waugh J; Keating GM; Plosker GL; Easthope S; Robinson DM
Drugs; 2006; 66(1):85-109. PubMed ID: 16398569
[TBL] [Abstract][Full Text] [Related]
9. Improving cardiovascular risk--applying evidence-based medicine to glucose-lowering therapy with thiazolidinediones in patients with type 2 diabetes.
Fisher M
Int J Clin Pract; 2009 Sep; 63(9):1354-68. PubMed ID: 19691621
[TBL] [Abstract][Full Text] [Related]
10. Different effects of thiazolidinediones on cardiovascular risk in patients with type 2 diabetes mellitus: pioglitazone versus rosiglitazone.
Simó R; Rodriguez A; Caveda E
Curr Drug Saf; 2010 Jul; 5(3):234-44. PubMed ID: 20210732
[TBL] [Abstract][Full Text] [Related]
11. [Glycemic control and cardiovascular benefit: What do we know today?].
Hanefeld M; Schönauer M; Forst T
Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
[TBL] [Abstract][Full Text] [Related]
12. Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality.
Pfützner A; Forst T
Expert Opin Pharmacother; 2006 Mar; 7(4):463-76. PubMed ID: 16503818
[TBL] [Abstract][Full Text] [Related]
13. Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk.
Zou C; Hu H
Vasc Health Risk Manag; 2013; 9():429-33. PubMed ID: 24023518
[TBL] [Abstract][Full Text] [Related]
14. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients.
Charbonnel B; Dormandy J; Erdmann E; Massi-Benedetti M; Skene A;
Diabetes Care; 2004 Jul; 27(7):1647-53. PubMed ID: 15220241
[TBL] [Abstract][Full Text] [Related]
15. Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.
Florkowski CM
Am J Cardiovasc Drugs; 2002; 2(1):15-21. PubMed ID: 14727995
[TBL] [Abstract][Full Text] [Related]
16. Type 2 diabetes, thiazolidinediones, and cardiovascular risk.
Taylor C; Hobbs FD
Br J Gen Pract; 2009 Jul; 59(564):520-4. PubMed ID: 19567003
[TBL] [Abstract][Full Text] [Related]
17. [Therapy with glitazones--a risk for cardiovascular disease?].
Rottlaender D; Michels G; Erdmann E; Hoppe UC
Dtsch Med Wochenschr; 2007 Dec; 132(49):2629-32. PubMed ID: 18050028
[TBL] [Abstract][Full Text] [Related]
18. [Proactive study: secondary cardiovascular prevention with pioglitazione in type 2 diabetic patients].
Scheen AJ; Lefèbvre PJ
Rev Med Liege; 2005 Nov; 60(11):896-901. PubMed ID: 16402538
[TBL] [Abstract][Full Text] [Related]
19. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
Khanderia U; Pop-Busui R; Eagle KA
Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
[TBL] [Abstract][Full Text] [Related]
20. [Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Eckert S; Erdmann E; Lundershausen R; Forst T; Scherbaum WA; Schnell O; Standl E; Schumm-Draeger PM; Tschöpe D; Walter H; Weber M
Dtsch Med Wochenschr; 2007 Dec; 132(49):2650-3. PubMed ID: 18050033
[No Abstract] [Full Text] [Related]
[Next] [New Search]
